Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly, Wegovy and Zepbound
Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Adults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy) in a head-to-head trial of the two injectables, Eli Lilly announced on Wednesday.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
BioSpace
8h
Lilly Pumps $3B Into Wisconsin Site as Compounders Close in on Tirzepatide
Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to ...
Hosted on MSN
3h
Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand
Eli Lilly LLY recently announced its plans to spend $3 billion to expand the manufacturing facility in Wisconsin that was ...
Seeking Alpha on MSN
1d
Lilly's Zepbound will first be given in the UK to those with 'highest clinical need'
Given the strong demand expected for
Eli
Lilly
's (NYSE:LLY) weight loss treatment Zepbound (
tirzepatide
) in the UK, the ...
STAT
1d
U.K. to restrict Eli Lilly’s obesity drug to patients with greatest need
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Zepbound
Wegovy
Glucagon-like peptide-1
Feedback